TG Therapeutics Inc
NASDAQ:TGTX
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
12.49
35.07
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one TGTX stock under the Base Case scenario is 23.8 USD. Compared to the current market price of 35.07 USD, TG Therapeutics Inc is Overvalued by 32%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
TG Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for TGTX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
TG Therapeutics Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
TG Therapeutics Inc
Balance Sheet Decomposition
TG Therapeutics Inc
Current Assets | 389.2m |
Cash & Short-Term Investments | 217.3m |
Receivables | 83.6m |
Other Current Assets | 88.3m |
Non-Current Assets | 12.1m |
Long-Term Investments | 947k |
PP&E | 7.7m |
Other Non-Current Assets | 3.4m |
Current Liabilities | 108.7m |
Accounts Payable | 93.5m |
Accrued Liabilities | 7.7m |
Other Current Liabilities | 7.5m |
Non-Current Liabilities | 115m |
Long-Term Debt | 102.5m |
Other Non-Current Liabilities | 12.4m |
Earnings Waterfall
TG Therapeutics Inc
Revenue
|
264.8m
USD
|
Cost of Revenue
|
-30.9m
USD
|
Gross Profit
|
233.9m
USD
|
Operating Expenses
|
-234.4m
USD
|
Operating Income
|
-505k
USD
|
Other Expenses
|
-13.9m
USD
|
Net Income
|
-14.4m
USD
|
Free Cash Flow Analysis
TG Therapeutics Inc
USD | |
Free Cash Flow | USD |
In the latest earnings call, TG Therapeutics reported third-quarter net sales of BRIUMVI at $83.3 million, marking a substantial 230% increase year-over-year. The company raised its full-year revenue guidance to $300-305 million, up from an earlier estimate of $220-260 million. BRIUMVI's profile remains strong, supported by favorable clinical data and growing market presence with nearly 1,100 prescribers targeting a 15% to 20% sequential sales growth in 2025. Additionally, the company plans to invest significantly in expanding commercial outreach and reducing infusion times, potentially positioning BRIUMVI as a leading therapy in the MS market.
What is Earnings Call?
TGTX Profitability Score
Profitability Due Diligence
TG Therapeutics Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Score
TG Therapeutics Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
TGTX Solvency Score
Solvency Due Diligence
TG Therapeutics Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Score
TG Therapeutics Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TGTX Price Targets Summary
TG Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for TGTX is 38.89 USD with a low forecast of 9.09 USD and a high forecast of 57.75 USD.
Dividends
Current shareholder yield for TGTX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
TGTX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 286 full-time employees. Its pipeline candidates include TG-1501 (Cosibelimab), TG-1701 (BTK inhibitor), TG-1801 (anti-CD47/anti-CD19 bispecific monoclonal antibody). Its UKONIQ (umbralisib) is developed for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed or refractory follicular lymphoma. The company has three programs in Phase III development for the treatment of patients with relapsing forms of multiple sclerosis and patients with chronic lymphocytic leukemia and several investigational medicines in Phase I clinical development. The company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Contact
IPO
Employees
Officers
The intrinsic value of one TGTX stock under the Base Case scenario is 23.8 USD.
Compared to the current market price of 35.07 USD, TG Therapeutics Inc is Overvalued by 32%.